This study could not clarify whether PD-1 inhibitor plus CTLA-4 inhibitor or PD-(L)1 inhibitor alone was sufficient to re-initiate or maintain the anti-tumor effect in such patients. This evidence concerns the gene CD274 and neoplasm.